Krsnaa Diagnostics Past Earnings Performance
Past criteria checks 2/6
Krsnaa Diagnostics has been growing earnings at an average annual rate of 7.2%, while the Healthcare industry saw earnings growing at 22.7% annually. Revenues have been growing at an average rate of 17.5% per year. Krsnaa Diagnostics's return on equity is 8.2%, and it has net margins of 10.2%.
Key information
7.2%
Earnings growth rate
-8.9%
EPS growth rate
Healthcare Industry Growth | 29.4% |
Revenue growth rate | 17.5% |
Return on equity | 8.2% |
Net Margin | 10.2% |
Next Earnings Update | 14 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Krsnaa Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 6,812 | 692 | 1,997 | 0 |
30 Jun 24 | 6,503 | 601 | 1,820 | 0 |
31 Mar 24 | 6,196 | 568 | 1,888 | 0 |
31 Dec 23 | 5,866 | 570 | 1,844 | 0 |
30 Sep 23 | 5,464 | 577 | 1,718 | 0 |
30 Jun 23 | 5,138 | 625 | 1,525 | 0 |
31 Mar 23 | 4,871 | 621 | 1,680 | 0 |
31 Dec 22 | 4,621 | 611 | 1,690 | 0 |
30 Sep 22 | 4,505 | 638 | 1,752 | 0 |
30 Jun 22 | 4,358 | 610 | 1,656 | 0 |
31 Mar 22 | 4,555 | 684 | 1,724 | 0 |
31 Dec 21 | 4,431 | 395 | 1,518 | 0 |
31 Mar 21 | 3,965 | 1,849 | 1,464 | 0 |
31 Dec 20 | 3,694 | 1,307 | 1,441 | 0 |
31 Mar 20 | 2,584 | -1,120 | 1,060 | 0 |
31 Mar 19 | 2,092 | -621 | 877 | 0 |
31 Mar 18 | 1,076 | -602 | 372 | 0 |
31 Mar 17 | 569 | -39 | 130 | 0 |
Quality Earnings: 543328 has a high level of non-cash earnings.
Growing Profit Margin: 543328's current net profit margins (10.2%) are lower than last year (10.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543328 has become profitable over the past 5 years, growing earnings by 7.2% per year.
Accelerating Growth: 543328's earnings growth over the past year (20%) exceeds its 5-year average (7.2% per year).
Earnings vs Industry: 543328 earnings growth over the past year (20%) did not outperform the Healthcare industry 29.6%.
Return on Equity
High ROE: 543328's Return on Equity (8.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 06:01 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Krsnaa Diagnostics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Bharat Celly | Equirus Securities Private Limited |
Cyndrella Carvalho | JM Financial Institutional Securities Limited |
Jainil Shah | JM Financial Institutional Securities Limited |